Moleculin Biotech (NASDAQ:MBRX) Trading Down 3.5% – Here’s Why

Shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) traded down 3.5% during trading on Wednesday . The company traded as low as $4.06 and last traded at $4.14. 104,290 shares traded hands during trading, a decline of 77% from the average session volume of 447,868 shares. The stock had previously closed at $4.29.

Wall Street Analysts Forecast Growth

MBRX has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $22.00 price objective (up from $4.00) on shares of Moleculin Biotech in a report on Thursday, December 11th. Wall Street Zen downgraded Moleculin Biotech to a “strong sell” rating in a research report on Friday, October 3rd. Roth Capital reiterated a “buy” rating on shares of Moleculin Biotech in a research report on Monday, December 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Moleculin Biotech currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.00.

Moleculin Biotech Trading Down 3.5%

The company has a market cap of $8.43 million, a price-to-earnings ratio of -0.13 and a beta of 1.62. The business has a 50-day moving average price of $6.58 and a 200 day moving average price of $10.75.

Moleculin Biotech (NASDAQ:MBRX) last issued its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.07. On average, analysts anticipate that Moleculin Biotech, Inc. will post -7.98 earnings per share for the current year.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.